The expression data identified genes with highly significant differential expression between poor and good responder xenografts to the three different drugs : 85 genes for doxorubicin , 74 genes for cisplatin , and 118 genes for ifosfamide .
In an attempt to find leads to such markers , we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide , doxorubicin , and cisplatin .
According to Sensitivity to Doxorubicin , Cisplatin , and Ifosfamide .
Current treatment regimens usually involve neoadjuvant and adjuvant chemotherapy with high - dose methotrexate , doxorubicin , cisplatin , and , more recently , ifosfamide .
Conclusions : The expression profiles contained several novel biomarker candidates that may help predict the responsiveness of osteosarcoma to doxorubicin , cisplatin , and ifosfamide .